Медицинская библиотека · The Tokai journal of experimental and clinical medicine · 2026

Treatment Outcomes of Durvalumab Combination Therapy in Patients with Biliary Tract Cancer.

Ito Hiroyuki, Kojima Seiichiro, Tazawa Yousuke, Omura Yuji, Yamaguchi Toru, Cho Tsubomi, Yoshihara Shihou, Nagata Junko, Hirose Shunji, Ogasawara Toshihito, Izumi Hideki, Kaneko Junichi, Suzuki Takayoshi

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

This study aimed to evaluate the efficacy and safety of gemcitabine, cisplatin, and durvalumab (GCD) combination therapy in patients with biliary tract cancer treated at our hospital.

METHODS

Nineteen patients diagnosed with biliary tract cancer and treated with durvalumab combination therapy at Tokai University Hachioji Hospital between February 1, 2023, and May 31, 2024, were included in this retrospective study.

RESULTS

The median overall survival was 13.7 months, and the median progression-free survival was 7.3 months, comparable to outcomes reported in the TOPAZ-1 trial.

CONCLUSION

GCD therapy demonstrated efficacy and safety similar to those observed in the TOPAZ-1 trial.

Для цитирования: Ito Hiroyuki, Kojima Seiichiro, Tazawa Yousuke, Omura Yuji, Yamaguchi Toru, Cho Tsubomi, Yoshihara Shihou, Nagata Junko, Hirose Shunji, Ogasawara Toshihito, Izumi Hideki, Kaneko Junichi, Suzuki Takayoshi. Treatment Outcomes of Durvalumab Combination Therapy in Patients with Biliary Tract Cancer.. The Tokai journal of experimental and clinical medicine. 2026.

Предметные рубрики MeSH

Humans Biliary Tract Neoplasms Antibodies, Monoclonal Antineoplastic Combined Chemotherapy Protocols Treatment Outcome Female Retrospective Studies Cisplatin Gemcitabine Aged Deoxycytidine Male Middle Aged Progression-Free Survival Aged, 80 and over

Подготовка и перевод публикации

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.